AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Submission of Audio recording of earnings call held on 27th May 2024 on Audited Financial Results for the year ended 31st March 2024. Q4FY24 Quarterly Result Announced for Aurobindo Pharma Ltd.
Pharmaceuticals company Aurobindo Pharma announced Q4FY24 results: Revenue from Operations increased by 17.1% YoY to Rs 7,580 crore with growth across the businesses US formulations (excluding Puerto Rico) revenue increased by 21.6% YoY to Rs 3,588 crore (USD 432 million) Europe formulation revenue increased by 10.4% YoY to Rs 1,832 crore (EUR 203 million) Growth Markets revenue increased by 49.5% YoY to Rs 852 crore (USD 103 million) ARV revenue increased by 31.5% YoY to Rs 238 crore (USD 29 million) API revenue remained flat YoY at Rs 1,019 crore (USD 123 million) EBITDA before Forex and Other income stood at Rs 1,687 crore; EBITDA margin of 22.3% Research & Development (R&D;) spend stood at Rs 392 crore, 5.2% of revenues (vs. Q3 FY24: 5.4%) Received final approval for 17 ANDAs including 4 specialty & injectable products from the USFDA Net Profit after Share of Profit/Loss of JV and minority interest at Rs 909 crore, vs. Rs 506 crore in Q4FY23 Basic & Diluted EPS grew by 79.5% YoY to Rs 15.51 per share Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are extremely delighted to report a strong performance for the quarter and the year, supported by the expansion into the new markets, product launches and stable pricing. Our improved capacity utilization has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year, while stabilizing the operations of the recently commercialized facilities.” Result PDF AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of News Paper Publications of financial results for the fourth quarter and year ended March 31, 2024
Aurobindo Pharma Q4 Net Profit Jumps To Rs 909 Crore
Revenue from operations rose to Rs 7,580 crore in the period under review. AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
Submission of Investors Presentation on audited financial results for the financial year ended March 31, 2024 AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Submission of Press Release on audited financial results for the financial year ended March 31, 2024 AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Change in Management
Intimation of reappointment / continuation of directors subject to approval of shareholders AUROBINDO PHARMA LTD. - 524804 - Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2024
Submission of Audited Financial Results for the fourth quarter and financial year ended on March 31, 2024 AUROBINDO PHARMA LTD. - 524804 - Board Meeting Outcome for Intimation Of Outcome Of Board Meeting
Submission of outcome of Board meeting held on 25th May 2024 AUROBINDO PHARMA LTD. - 524804 - Classification Of US FDA Inspection At Unit III Of Eugia Pharma Specialities Ltd. (Our Wholly Owned Subsidiary)
Intimation of classification of US FDA inspection at Unit III of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.